Tag: 100-200

On November 13, 2008, Yamashita, Haruhisa; Odai, Osamu; Harada, Hiroshi; Iwata, Mitsutaka published a patent.Formula: C6H8N2O2S The title of the patent was Preparation of fused heterocyclic derivatives as glucokinase (GK) activators. And the patent contained the following:

Title compounds I [A = -N(R3)(CH2)m-, -N(R3)CO(CH2)m- or -N(R3)SO2(CH2)m-; m = 0-2; X1, X2 = -CO-, -CS- or -C(R4)(R5)-; X3 = -C(R4)(R5)-; R1 = H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R2 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R3 = H, (un)substituted alkyl or (un)substituted cycloalkyl; R4, R5 = H, halo or (un)substituted alkyl; n = 1 or 2] or their pharmaceutically acceptable salts were prepared For example, Pd2(dba)3 catalyzed reaction of compound II [R = Cl], e.g., prepared from Et 4-oxopiperidine-3-carboxylate hydrochloride in 3 steps, with 2-aminothiazole afforded compound II [R = thiazol-2-ylamino], which showed 328% GK activation. Compounds I are claimed useful for the treatment of diabetes. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Formula: C6H8N2O2S

The Article related to fused heterocycle preparation glucokinase gk activator, diabetes treatment fused heterocycle preparation gk activation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C6H8N2O2S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On July 21, 2011, Kallander, Lara S.; Lawhorn, Brian Griffin; Philip, Joanne; Zhao, Yongdong published a patent.Formula: C6H8N2O2S The title of the patent was 3-[(6-Aminopyrimidin-4-yl)amino]benzenesulfonamide compounds useful as TNNI3K inhibitors, their preparation, and methods of use in the treatment of congestive heart failure. And the patent contained the following:

Title compounds I are disclosed [wherein R1 = C1-4 alkyl; R2 = H, halo; R3 = H, halo, (un)substituted alkyl or alkoxy, aryl, OH, cycloalkyl, alkylthio, amino, (di)(alkyl)amino; R4 = H, halo, (un)substituted alkyl or alkoxy, OH, (halo)alkylthio, alkylsulfonyl, (un)substituted amino; R5 = H; or R4 and R5 form a 5 or 6 membered ring, optionally substituted or containing one or two addnl. N/O/S atoms; R6 = alky(en/yn)yl, cycloalkyl, (un)substituted (hetero)aryl; and salts]. I are inhibitors of cardiac troponin I-interacting kinase (TNNI3K), also known as CARK (for cardiac ankyrin repeat kinase), a protein kinase that exhibits highly selective expression for cardiac tissues and which has been shown to interact with components of the sarcomere, including troponin I. Approx. 380 compounds I are claimed as the free base, and were prepared as salts and/or free bases. Numerous intermediates were also prepared For instance, the intermediate 3-[(6-chloro-4-pyrimidinyl)amino]-N-methylbenznesulfonamide and 3-biphenylamine were microwaved together in isopropanol in the presence of concentrated HCl at 150° for 20 min to give invention compound II, isolated as the trifluoroacetate. In bioassays using human TNNI3K, I exhibited pXC50 ≥ approx. 6.0. For instance, two compounds I inhibited hTNNI3K with a mean pXC50 of approx. 7.0. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Formula: C6H8N2O2S

The Article related to pyrimidinylamino benzenesulfonamide preparation tnni3k inhibitor treatment congestive heart failure, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C6H8N2O2S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On June 7, 2018, Wunderlich, Winfried; Huber, Lukas A.; Leban, Johann Jakob; Pato, Janos; Oerfi, Laszlo; Frigyes, Waczek; Banhegyi, Peter; Sipos, Anna; Szantai-Kis, Csaba published a patent.Category: thiazole The title of the patent was Preparation of 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors for the treatment and prophylaxis of cancer. And the patent contained the following:

The invention relates to preparation of pyrazolopyrimidinones of formulas I and II wherein X1 and X4 each independently H, halo, C1-6 alkoxy; X2 is H or halo; X3 is H, COOH, etc., as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and treatment of cancer and other proliferative diseases. Furthermore the invention relates to processes for the preparation of said 3-amino-pyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the invention. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Category: thiazole

The Article related to pyrazolopyrimidinone preparation cdk inhibitor proliferative disease cancer treatment prophylaxis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Goswami, K. V.; Parajapati, S. N.; Goswami, T. K.; Chaudhari, H. D.; Parmar, Kokila A. published an article in 2019, the title of the article was Spectral and microbial screening of one-pot multicomponent synthesis of fused quinazolinone derivatives.Quality Control of 4-Phenylthiazol-2-amine And the article contains the following content:

Heterocyclic compounds containing 2-chloro-3-formyl pyridine and 2-amino thiazole quinqzolin-6(7H)-one I (R = H, Me, OMe; R1 = H, OMe, OH; R2 = H, Me) are reported to possess significant biol. activity. Synthesis of fused quinazolinone derivatives I have been described. The above synthesized compounds have been evaluated for their antimicrobial activity. Among the series containing some of the compounds showed promising results against standard drugs. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Quality Control of 4-Phenylthiazol-2-amine

The Article related to pyridinyl dihydro thiazoloquinazolinone preparation antibacterial antifungal activity, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 4-Phenylthiazol-2-amine

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On May 31, 2021, Wang, Jie; Battini, Narsaiah; Ansari, Mohammad Fawad; Zhou, Cheng-He published an article.Related Products of 24295-03-2 The title of the article was Synthesis and Biological Evaluation of Quinazolonethiazoles as New Potential Conquerors towards Pseudomonas Aeruginosa. And the article contained the following:

Novel quinazolonthiazoles were designed and synthesized as new potential antimicrobial agents by facile multi-step procedure from o-aminobenzoic acids and 2-acetylthiazole. A series of biol. evaluation showed that compound I [X = 7-Cl; R = O(CH2)5CH3] was the most effective quinazolonethiazole with superior activity to reference drugs chloramphenicol and norfloxacin. This active mol. displayed unobvious bacterial resistance against P. aeruginosa, the low toxicity to normal hepatocytes, suitable pharmacokinetics and drug-likeness. The preliminary biol. interaction suggested that quinazolonethiazole I [X = 7-Cl; R = O(CH2)5CH3] might induce bacterial death by disturbing the membrane permeability, while preventing bacteria from growth by integrating into DNA and binding with topoisomerase IV. These findings provided significant background for the further development of quinazolonethiazoles as new potential drugs in combating drug-resistant pathogens. The experimental process involved the reaction of 2-Acetylthiazole(cas: 24295-03-2).Related Products of 24295-03-2

The Article related to quinazolonethiazole preparation antibacterial antifungal sar mol docking, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 24295-03-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On December 31, 2020, Nizamuddin, N. D.; Abdul Ahad, Hindustan; Devanna, Nayakanti published an article.Application In Synthesis of 4-Phenylthiazol-2-amine The title of the article was Synthesis and molecular docking studies of some 1,2-dimethyl-3(4-substituted phenyl-1,3-thiazol-2-yl)2,3-dihydroquinazolin-4(1H)-ones as anticancer agents. And the article contained the following:

Synthesis of 1, 2-dimethyl-3(4-substituted phenyl-1,3-thiazol-2-yl)2,3-dihydro quinazolin-4(1H)-ones derivatives I [R = 4-Me, 2-OH, 4-Cl, etc.] was effected by refluxing 1,2-dimethylbenzoxazine-4-one with different 4-substituted phenyl-1,3-thiazol-2-amines. Synthesized compoundsI were characterized through elemental anal., IR, proton NMR, and Carbon-13 NMR. Mol. docking studies were carried out using Schrodinger Glide (version 2020_1) which was docked into selective P38alpha and Activin A Receptor Type 1 (ACVR1) Activin receptor-like kinase-2 (ALK2) kinase with Protein Data Bank (PDB) code 3GC7, 6GI6. Based on the docking score of synthesized quinazolin-4-one derivatives, I co-crystallized ligands interaction was evaluated with 5-fluorouracil (5-FU) as a reference drug. Compounds I [R = H, 4-MeO, 3-NH2, 2,4-OH] with P38alpha, I [R = 2-OH, 3-NH2, 4-Cl, 2,4-OH] with ACVR1 (ALK2) kinase score were -7.265, -7.078, -7.058 and -6.836; -8.929, -8.749, -8.735 and -8.464 Kcal/mol against enzymes responsible for cancer treatment. The results indicated that quinazolin-4-one derivatives I scored better than ligand and 5-FU. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Application In Synthesis of 4-Phenylthiazol-2-amine

The Article related to dimethyl phenyl thiazolyl dihydroquinazolinone preparation mol docking, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Application In Synthesis of 4-Phenylthiazol-2-amine

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On December 26, 2017, Mai, Xi; Feng, Lihua; Liao, Yijing; Xu, Zhaoxing published a patent.SDS of cas: 64987-16-2 The title of the patent was Purine hydroxamic acid derivative and its preparation method and application in preparing drug for treating histone deacetylases mediated disease. And the patent contained the following:

The title purine hydroxamic acid derivative has structural formula I, wherein R1 is H or Me; R2 is H, halogen, alkyl, alkoxyl, alkylamino, hydroxyl, cyano or nitro. The derivative and its pharmaceutical composition can be used in preparing drug for treating histone deacetylases mediated disease, and has obvious inhibiting effect on histone deacetylases and anti-tumor activity. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).SDS of cas: 64987-16-2

The Article related to purine hydroxamic acid preparation histone deacetylase antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 22, 2009, Hahn, Michael G.; Becker, Eva-Maria; Knorr, Andreas; Schneider, Dirk; Stasch, Johannes-Peter; Schlemmer, Karl-Heinz; Wunder, Frank; Stoll, Frederike; Heitmeier, Stefan; Muenter, Klaus; Griebenow, Nils; Lampe, Thomas; El Sheikh, Sherif; Li, Volkhart Min-Jian published a patent.HPLC of Formula: 64987-16-2 The title of the patent was Preparation of phthalazinones as soluble guanylate cyclase inhibitors. And the patent contained the following:

Title compounds I [X = L1-M-L2CO2H; L1 = bond, methylene, etc.; M = phenylene, 5 or 6-membered heteroaryl with provisos; L2 = bond, methylene with provisos; A = 5-7 membered heterocycle ring with provisos; R1 = H, alkyl, cycloalkyl; R2 = H, halo, CN, etc.; R3 = alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, NaOH/dioxane/H2O mediated saponification of ester II [Y = Me] afforded acid II [Y = H]. In soluble guanylate cyclase inhibition assays, 48-examples of compounds I exhibited MEC values ranging from 0.1-300 nM. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).HPLC of Formula: 64987-16-2

The Article related to phthalazinone preparation soluble guanylate cyclase inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.HPLC of Formula: 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 15, 2009, Hahn, Michael; Becker, Eva-Maria; Knorr, Andreas; Schneider, Dirk; Stasch, Johannes-Peter; Schlemmer, Karl-Heinz; Wunder, Frank; Stoll, Friederike; Heitmeier, Stefan; Muenter, Klaus; Griebenow, Nils published a patent.Category: thiazole The title of the patent was Preparation of phthalazinones as soluble guanylate cyclase inhibitors. And the patent contained the following:

Title compounds I [X = L1-M-L2CO2H; L1 = bond, methylene, etc.; M = phenylene, 5 or 6-membered heteroaryl with provisos; L2 = bond, methylene with provisos; A = 5-7 membered heterocycle ring with provisos; R1 = H, alkyl, cycloalkyl; R2 = H, halo, CN, etc.; R3 = alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, NaOH/dioxane/H2O mediated saponification of ester II [Y = Me] afforded acid II [Y = H]. In soluble guanylate cyclase inhibition assays, 19 examples of compounds I exhibited MEC values ranging from 1-300 nM. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Category: thiazole

The Article related to phthalazinone preparation soluble guanylate cyclase inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Category: thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On April 25, 2013, Ogamino, Takahisa; Yamazaki, Yukiyoshi; Tanikawa, Shin; Okuda, Ayumu; Fukuda, Tomoaki; Tokuda, Okihisa; Miyake, Yoshiharu; Itoh, Shinsuke; Ishiwata, Hiroyuki published a patent.Product Details of 64987-16-2 The title of the patent was Preparation of spiroindoline compounds for activating glucokinase. And the patent contained the following:

Title compounds I [ring A = nitrogen-containing heterocyclyl; R1, R2 = independently H, halo, haloalkyl, etc.; R3 = H, (un)substituted alkyl, -COR7, etc.; R7 = H, (un)substituted alkyl, haloalkyl, etc.; R4 = H, halo, cyano, etc.; or salts or solvates thereof], useful for the treatment of diabetes, glucose intolerance, metabolic syndrome, etc., were prepared For example, reaction of 2-amino-5-chlorothiazole·HCl with 4-nitrophenyl chloroformate, treatment with tert-Bu 5-bromospiro[indoline-3,3′-pyrrolidine]-1′-carboxylate, deprotection using CF3CO2H, and acetylation afforded compound II. The invention compounds activated glucokinase activity in vitro assay, e.g., III showed 1192% activation at 1 μmol/L. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Product Details of 64987-16-2

The Article related to spiroindoline preparation glucokinase activator, diabetes glucose intolerance metabolic syndrome treatment spiroindoline glucokinase activation, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Product Details of 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica